

Synthesis of 2-(polyfluoromethyl)pyrimido[1,2-*a*]benzimidazole-4-carbaldehyde derivatives


Danila V. Belyaev,^a Dmitrii L. Chizhov,^{*a} Mikhail I. Kodess,^{a,b}
Marina A. Ezhikova,^a Gennady L. Rusinov^{a,b} and Valery N. Charushin^{a,b}

^a I. Ya. Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, 620990 Ekaterinburg, Russian Federation. Fax: +7 343 369 3058; e-mail: dlchizhov@ios.uran.ru

^b Institute of Chemical Engineering, Ural Federal University, 620002 Ekaterinburg, Russian Federation

DOI: 10.1016/j.mencom.2019.05.002

A simple and efficient synthesis of 2- R^F -pyrimido[1,2-*a*]benzimidazole-4-carbaldehyde derivatives comprises the reaction between 3-(polyfluoroacetyl)pyruvaldehyde dimethyl acetals and 2-aminobenzimidazole. The effects of fluorinated substituents in 3-(polyfluoroacetyl)pyruvaldehyde dimethyl acetals and the reaction conditions on regiochemical outcome of this reaction have been estimated.



Azolopyrimidines and their fused analogues are of considerable interest due to their wide spectrum of biological activities. Indeed, a number of pyrimido[1,2-*a*]benzimidazoles proved to exhibit antimicrobial,¹ antioxidant,² antineurodegenerative,³ immunotropic,⁴ and antiproliferative⁵ activities.


Introduction of fluorinated substituents into organic molecules appears to be an effective tool to change their physical and chemical properties, as well as biological activity.⁶ A few examples of pyrimido[1,2-*a*]benzimidazoles bearing a fluorinated alkyl group in the pyrimidine ring have been described so far.⁷ Compounds of this family exhibit herbicide^{7(a)} and DNA-topoisomerase I enzyme inhibitor^{7(f)} activities. Pyrimidobenzimidazoles bearing a fluoroalkyl group (usually trifluoromethyl) have been obtained by reacting 2-aminobenzimidazole with fluoroalkylated β -dicarbonyl compounds,^{7(a)} 3-trifluoroacetylated lactams,⁸ 4-trifluoroacetyl-2,3-dihydropyrroles,⁹ β -trifluoroacetylvinyl sulfones,^{7(d)} and polyfluoroacetyl alkoxy enones.^{7(b),(f)} However, further modifications of these compounds were not performed. Therefore, introduction of a versatile functional group into the structure of fluorinated pyrimidobenzimidazoles can be regarded as a useful approach to tune their biological activity.

Recently we have described a new functionalized fluorinated building block containing adjacent 1,3-dicarbonyl and acetal

fragments, namely 3-(polyfluoroacetyl)pyruvaldehyde dimethyl acetals [1-(polyfluoromethyl)-4,4-dimethoxybutane-1,3-diones] **1a,b**.¹⁰ The dimethyl acetal group in compounds **1a,b** provides wide opportunities for modifications of heterocyclic compounds prepared by reaction of 1,3-dicarbonyl moiety with *N,N'*-binucleophiles. In this communication, we report the regioselective synthesis of dimethyl acetals, hydrates, and semicarbazones of 2-polyfluoroalkyl-substituted pyrimido[1,2-*a*]benzimidazole-4-carbaldehydes.

We have found that 1,1,1-trifluoro-5,5-dimethoxypentane-2,4-dione **1a** reacted regioselectively with 2-aminobenzimidazole in refluxing methanol to give a mixture of dimethyl acetals of 2- CF_3 -substituted pyrimido[1,2-*a*]benzimidazole-4-carbaldehyde **2a** and regioisomeric 4- CF_3 -substituted pyrimido[1,2-*a*]benzimidazole-2-carbaldehyde **3a** in a ratio of ~91:9 (19F NMR data for the crude reaction mixture, Scheme 1, Table 1, entry 1).

Further on, we have found that pyrimido[1,2-*a*]benzimidazole **2a** is formed nearly regioselectively when the reaction was carried out either in acetonitrile, or in the presence of 3 equiv. of triethyl



Scheme 1

Table 1 Influence of reaction conditions on the 2:3 ratio and yields of the products.

Entry	Diketone	Solvent	$T/^\circ C$	t/h	Ratio of 2:3 ^a	Isolated yields ^b (%)
1	1a	MeOH	64	6	91:9	24
2	1a	MeCN	82	6	95:5	60
3	1a	MeCN/B(OEt) ₃	82	6	98:2	70 (67)
4	1a	CF ₃ CH ₂ OH	78	6	60:40	55
5	1a	(CF ₃) ₂ CHOH	59	6	59:41	62
6	1a	AcOH	82	3	74:26	45
7	1a	AcOH	116	0.5	69:31	32
8	1b	MeCN	82	6	55:45	86
9	1b	MeCN/B(OEt) ₃	82	6	95:5	92 (86)
10	1b	CF ₃ CH ₂ OH	78	6	45:55	90
11	1b	(CF ₃) ₂ CHOH	59	6	45:55	91

^aBased on the ¹⁹F NMR data for crude reaction mixtures. ^bMixture of compounds **2** and **3** after column chromatography, and pure **2** in parentheses.

borate (Table 1, entries 2 and 3). Previously, we have shown that the use of trialkyl borates was effective in the selective amination of fluorinated 1,3-diketones with 1,2-diaminobenzene.¹¹ The application of triethyl borate in the reaction under study increased its yield by 10% and improved the regioselectivity to some extent, thus enabling us to isolate product **2a** in 67% yield.[†]

It is known that the use of 2,2,2-trifluoroethanol and 1,1,1,3,3,3-hexafluoropropan-2-ol as solvents can dramatically change the regioselectivity of reactions between fluorinated 1,3-diketones and substituted hydrazines.¹² When we carried out the reactions in these fluorinated alcohols, the fraction of **3a** was increased up to 40% (see Table 1, entries 4 and 5). However, enriched in **3a** sample (~90%) was obtained in only 9% yield after double chromatography.[‡] Noteworthy, yields of the reaction products and fraction of **3a** in the reaction mixtures were lower when acetic acid was used as solvent (entries 6 and 7).

The most suitable conditions were applied to react 1,1-difluoro-5,5-dimethoxypentane-2,4-dione **1b** with 2-aminobenzimidazole (see Table 1, entries 8–11). Interestingly, this reaction was not regioselective in acetonitrile (entry 8), whereas application of triethyl borate provided a good regioselectivity for the heterocyclization (entry 9) when pure 2-HCF₂-substituted pyrimido[1,2-*a*]benzimidazole-4-carbaldehyde dimethyl acetal **2b** was obtained in 86% yield after a simple crystallization.[†] Regioisomeric 4-HCF₂-substituted pyrimido[1,2-*a*]benzimidazole-2-carbaldehyde dimethyl acetal **3b** better formed in fluorinated alcohols was isolated in 36% yield by chromatography followed by recrystallization (entries 10 and 11).[‡]

The structures of pyrimido[1,2-*a*]benzimidazoles **2** and **3** were determined by elemental analysis, ¹H, ¹⁹F, ¹³C and ¹⁵N NMR spectroscopy, and unambiguously assigned on the basis of 2D NMR experiments ¹H-¹³C HSQC, ¹H-¹³C HMBC, ¹H-¹⁵N HMBC, and ¹H-¹H NOESY (Figure 1). The most notable differences between isomers **2** and **3** have been manifested in 2D ¹H-¹⁵N HMBC experiments. In the NMR spectra of compounds **2a,b**, protons H-6 and H-11 correlate with the same upfield nitrogen




Figure 1 Diagnostic chemical shifts (in ppm) of regioisomeric pyrimido[1,2-*a*]benzimidazoles **2** and **3**.

N-5 (δ_N 170–172 ppm), while in the NMR spectra of **3a,b** cross-peaks (H-11, N-1) and (H-6, N-5) are observed. The NOESY experiments for compounds **2a,b** have revealed links between H-11 and OMe protons and H-6 of the benzene ring. In the ¹H NMR spectra of isomers **2** (CDCl₃), singlets for the acetal proton H-11 are located at 6.09–6.12 ppm, whereas the corresponding signals for regioisomers **3** are shifted upfield (δ_H 5.32–5.3 ppm). This difference can be explained by a deshielding effect of the benzimidazole fragment in case of compounds **2**. Additionally, in the ¹H NMR spectrum of **3b**, the diagnostic triplet of HCF₂-group proton is more deshielded (δ_H 7.29 ppm) in comparison with that of **2b** (δ_H 6.68 ppm). In the ¹⁹F NMR spectrum of **2a**, the CF₃ group appears as a singlet at δ_F 92.9 ppm. In case of regioisomer **3a**, the signal of the same fluorinated group is shifted downfield (δ_F 94.5 ppm) and appears as a doublet with small J_{HF} 2.2 Hz. In ¹⁹F NMR spectra of **2b** and **3b**, the doublets for the HCF₂ group were observed at 45.8 and 40.9 ppm, respectively. In the

[†] *Regioselective synthesis of 2-R^F-pyrimido[1,2-*a*]benzimidazole-4-carbaldehyde dimethyl acetals 2a,b.* Compounds **1** (1 mmol), 2-aminobenzimidazole (1.05 mmol, 0.140 g) and B(OEt)₃ (3 mmol, 0.438 g) were refluxed in MeCN (30 ml) for 6 h. The mixture was cooled and diluted with water (100 ml). The resulting precipitate was filtered off, washed with water (3 × 10 ml), dried in air, and recrystallized from hexane to give corresponding product **2**.


*2-Trifluoromethyl-4-(dimethoxymethyl)pyrimido[1,2-*a*]benzimidazole 2a.* Yellow powder, yield 0.21 g (67%), mp 141–142 °C. ¹H NMR (500 MHz, CDCl₃) δ : 3.48 (s, 6H, 2OMe), 6.13 (s, 1H, H-11), 7.49 (ddd, 1H, H-7, J 8.6, 7.2, 1.1 Hz), 7.52 (s, 1H, H-3), 7.63 (ddd, 1H, H-8, J 8.2, 7.2, 1.0 Hz), 8.05 (d, 1H, H-9, J 8.2 Hz), 8.27 (d, 1H, H-6, J 8.6 Hz). ¹⁹F NMR (470 MHz, CDCl₃) δ : 92.87 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ : 53.22 (s, OMe), 96.63 (C¹¹), 101.51 (q, C³, $^3J_{CF}$ 1.5 Hz), 116.68 (C⁶), 120.26 (q, CF₃, $^1J_{CF}$ 276.1 Hz), 120.56 (C⁹), 123.70 (C⁷), 126.58 (C^{5a}), 127.33 (C⁸), 144.80 (C^{9a}), 148.30 (C⁴), 149.14 (C^{10a}), 151.46 (q, C², $^2J_{CF}$ 37.2 Hz). ¹⁵N NMR (50 MHz, CDCl₃) δ : 171.9 (N⁵), 223.1 (N¹⁰), 274.5 (N¹). Found (%): C, 54.11; H, 3.87; N, 13.43; F, 18.22. Calc. for C₁₄H₁₂F₃N₃O₂ (%): C, 54.02; H, 3.89; N, 13.50; F, 18.31.

*2-Difluoromethyl-4-(dimethoxymethyl)pyrimido[1,2-*a*]benzimidazole 2b.* Yellow powder, yield 0.25 g (86%), mp 128–130 °C. ¹H NMR (500 MHz, CDCl₃) δ : 3.47 (s, 6H, 2OMe), 6.08 (s, 1H, H-11), 6.68 (t, 1H, HCF₂, $^2J_{HF}$ 54.7 Hz), 7.47 (ddd, 1H, H-7, J 8.6, 7.2, 1.3 Hz), 7.50 (s, 1H, H-3), 7.62 (ddd, 1H, H-8, J 8.3, 7.2, 1.1 Hz), 8.06 (d, 1H, H-9, 3J 8.3 Hz), 8.26 (d, 1H, H-6, 3J 8.6 Hz). ¹⁹F NMR (470 MHz, CDCl₃) δ : 45.90 (d, HCF₂, $^2J_{FH}$ 54.7 Hz). ¹³C NMR (126 MHz, CDCl₃) δ : 53.14 (s, OMe), 96.93 (C¹¹), 101.18 (C³), 113.55 (t, HCF₂, $^1J_{CF}$ 242.0 Hz), 116.48 (C⁶), 120.76 (C⁹), 123.16 (C⁷), 126.75 (C⁸), 126.88 (C^{5a}), 145.29 (C^{9a}), 147.61 (C⁴), 150.01 (C^{10a}), 156.43 (t, C², $^2J_{CF}$ 28.5 Hz). ¹⁵N NMR (50 MHz, CDCl₃) δ : 170.4 (N⁵), 224.5 (N¹⁰), 276.4 (N¹). Found (%): C, 57.01; H, 4.40; N, 14.29; F, 12.73. Calc. for C₁₄H₁₃F₂N₃O₂ (%): C, 57.34; H, 4.47; N, 14.33; F, 12.96.

[‡] *Preparation of 4-R^F-pyrimido[1,2-*a*]benzimidazole-2-carbaldehyde dimethyl acetals 3a,b.* Compound **1** (2.5 mmol) and 2-aminobenzimidazole (2.63 mmol, 0.350 g) were refluxed in trifluoroethanol (10 ml) for 6 h. The mixture was evaporated to dryness and twice chromatographed (silica gel, eluent CHCl₃).

*4-Trifluoromethyl-2-(dimethoxymethyl)pyrimido[1,2-*a*]benzimidazole 3a.* Yellow powder, yield 0.07 g (9%). Purity ~90% (according to NMR data). Additionally 0.36 g (46%) of **2a**+**3a** mixture was isolated. The total yield was ~55%. ¹H NMR (500 MHz, CDCl₃) δ : 3.58 (s, 6H, 2OMe), 5.33 (s, 1H, H-11), 7.56 (ddd, 1H, H-7, J 8.6, 7.2, 1.3 Hz), 7.65 (s, 1H, H-3), 7.69 (ddd, 1H, H-8, J 8.3, 7.2, 0.9 Hz), 8.11 (dm, 1H, H-6, J 8.6 Hz), 8.17 (d, 1H, H-9, J 8.3 Hz). ¹⁹F NMR (470 MHz, CDCl₃) δ : 94.68 (d, CF₃, J_{FH} 2.2 Hz). ¹³C NMR (126 MHz, CDCl₃) δ : 55.45 (s, OMe), 103.51 (q, C³, $^3J_{CF}$ 5.3 Hz), 104.57 (C¹¹), 114.31 (q, C⁶, $^5J_{CF}$ 5.9 Hz), 119.69 (q, CF₃, $^1J_{CF}$ 274.2 Hz), 120.98 (C⁹), 123.96 (C⁷), 125.90 (C^{5a}), 127.07 (C⁸), 135.46 (q, C⁴, $^2J_{CF}$ 37.9 Hz), 144.34 (C^{9a}), 149.58 (C^{10a}), 162.70 (C²). ¹⁵N NMR (50 MHz, CDCl₃) δ : 160.1 (N⁵), 224.1 (N¹⁰), 284.6 (N¹).

*4-Difluoromethyl-2-(dimethoxymethyl)pyrimido[1,2-*a*]benzimidazole 3b.* Recrystallization from hexane, yellow powder, yield 0.26 g (36%), mp 149–152 °C. Additionally 0.40 g (54%) of **2b**+**3b** mixture was isolated. The total yield was ~90%. ¹H NMR (500 MHz, CDCl₃) δ : 3.55 (s, 6H, 2OMe), 5.30 (s, 1H, H-11), 7.24 (t, 1H, HCF₂, $^2J_{HF}$ 52.6 Hz), 7.43 (s, 1H, H-3), 7.46 (ddd, 1H, H-7, J 8.5, 7.3, 1.1 Hz), 7.60 (t, 1H, H-8, J 7.7 Hz), 8.01 (d, 1H, H-6, J 8.5 Hz), 8.04 (d, 1H, H-9, J 8.3 Hz). ¹⁹F NMR (470 MHz, CDCl₃) δ : 40.86 (d, HCF₂, $^2J_{FH}$ 52.4 Hz). ¹³C NMR (126 MHz, CDCl₃) δ : 55.30 (s, OMe), 102.99 (t, C³, $^3J_{CF}$ 7.7 Hz), 104.70 (s, C¹¹), 109.84 (t, HCF₂, $^1J_{CF}$ 243.0 Hz), 114.25 (t, C⁶, $^5J_{CF}$ 4.7 Hz), 120.90 (C⁹), 123.40 (C⁷), 126.22 (C^{5a}), 126.65 (C⁸), 140.26 (t, C⁴, $^2J_{CF}$ 25.6 Hz), 144.58 (C^{9a}), 149.80 (C^{10a}), 162.91 (C²). ¹⁵N NMR (50 MHz, CDCl₃) δ : 163.8 (N⁵), 224.1 (N¹⁰), 281.3 (N¹). Found (%): C, 57.23; H, 4.37; N, 14.35; F, 13.05. Calc. for C₁₄H₁₃F₂N₃O₂ (%): C, 57.34; H, 4.47; N, 14.33; F, 12.96.



Scheme 2 Reagents and conditions: i, HCl (aq.), reflux, 1 h, then NaHCO₃ (pH 6–7); ii, NH₂CONHNH₂·HCl, AcOH, reflux, 1 h, then AcONa.

¹³C NMR spectra of isomers **3**, the resonance signal of C-6 carbon is splitted into a quartet (⁵J_{CF} 5.9 Hz for **3a**) or triplet (⁵J_{CF} 4.7 Hz for **3b**) due to through-space C–F coupling.

Compounds **2a** and **2b**, which were isolated in higher yields and purities, were hydrolyzed and derivatized to demonstrate their synthetic potentials (Scheme 2). The hydrolysis of compounds **2** proved to furnish hydrates of the corresponding heterocyclic aldehydes **4**.[§] The presence of geminal diol moiety was confirmed owing to one-proton triplets (³J_{HH} 6.8 Hz) at δ 6.55–6.57 ppm and two-proton doublets (³J_{HH} 6.8 Hz) at δ 7.54–7.61 ppm observed in the ¹H NMR spectra of compounds **4a** and **4b**. The first signal is transformed into a broad singlet after the addition of CD₃COOD, whereas the second one proved to be disappearing. Therefore, these signals can be assigned unambiguously to H-11 and OH protons, respectively. Noteworthy, additional sets of signals with ~6–10% integral intensities were detected in the ¹H and ¹⁹F NMR spectra of hydrates **4a** and **4b**, and they were assigned to the corresponding heterocyclic carbaldehydes, since characteristic singlets of the aldehyde group were expected to be observed at δ_H 10.4 ppm.

Compounds **4** proved to undergo decomposition in the course of the dehydration reaction. Nevertheless, they react smoothly with semicarbazide in refluxing acetic acid to afford the corresponding semicarbazones **5a** and **5b** in high yields.[§] Their structures were confirmed by elemental analysis, ¹H, ¹⁹F and ¹³C NMR spectroscopy.

In conclusion, the reaction of 1-polyfluoroalkyl-4,4-dimethoxybutane-1,3-diones with 2-aminobenzimidazole has been accomplished, and an efficient approach to particular derivatives (dimethyl acetal, hydrate, and semicarbazone) of 2-polyfluoroalkyl-substituted pyrimido[1,2-*a*]benzimidazole-4-carbaldehydes has been developed.

This study was performed within framework of the subject AAAA-A19-119011790132-7 of the State target. Analytical studies were carried out using equipment of the Center for Joint Use ‘Spectroscopy and Analysis of Organic Compounds’ at the I. Ya. Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences.

[§] General remarks, synthesis of hydrates and semicarbazones of 2-R^F-pyrimido[1,2-*a*]benzimidazole-4-carbaldehydes **4** and **5**, and the characterization data for all synthesized compounds are given in Online Supplementary Materials.

Online Supplementary Materials

Supplementary data associated with this article can be found in the online version at doi: 10.1016/j.mencom.2019.05.002.

References

- (a) O. Algul, A. Meric, S. Polat, N. D. Yuksek and M. S. Serin, *Cent. Eur. J. Chem.*, 2009, **7**, 337; (b) N. M. Shah and H. S. Joshi, *Int. Lett. Chem. Phys. Astron.*, 2014, **25**, 56.
- C. G. Neochoritis, T. Zarganes-Tzitzikas, C. A. Tsoleridis, J. Stephanidou-Stephanatou, C. A. Kontogiorgis, D. J. Hadjipavlou-Litina and T. Choli-Papadopoulou, *Eur. J. Med. Chem.*, 2011, **46**, 297.
- P. Pavlov and B. Winblad, *Patent WO 2017168137 A1*, 2017.
- W. Nawrocka and M. Zimecki, *Arch. Pharm. Pharm. Med. Chem.*, 1998, **331**, 249.
- (a) A. Nowicka, H. Liszkiewicz, W. P. Nawrocka, J. Wietrzyk, K. Kempiriska and A. Dryś, *Cent. Eur. J. Chem.*, 2014, **12**, 1047; (b) W. P. Nawrocka, B. Sztuba, A. Dryś, J. Wietrzyk, J. Kosendiak and A. Opolski, *Pol. J. Chem.*, 2006, **80**, 279.
- (a) R. Filler and R. Saha, *Future Med. Chem.*, 2009, **1**, 777; (b) B.-C. Wang, L.-J. Wang, B. Jiang, S.-Y. Wang, N. Wu, X.-Q. Li and D.-Y. Shi, *Mini-Rev. Med. Chem.*, 2017, **17**, 683; (c) N. V. Palysaeva, N. S. Boltacheva, P. A. Slepukhin, M. G. Pervova, V. I. Filyakova, A. B. Sheremetev and V. N. Charushin, *Mendeleev Commun.*, 2018, **28**, 126; (d) J.-P. Bégué and D. Bonnet-Delpon, *Bioorganic and Medicinal Chemistry of Fluorine*, Wiley, Hoboken, NJ, 2008; (e) V. M. Muzalevskiy, M. N. Mamedzade, V. A. Chertkov, V. A. Bakulev and V. G. Nenajdenko, *Mendeleev Commun.*, 2018, **28**, 17; (f) J.-P. Bégué and D. Bonnet-Delpon, in *Fluorine and Health. Molecular Imaging, Biomedical Materials and Pharmaceuticals*, eds. A. Tressaud and G. Haufe, Elsevier, Amsterdam, 2008, pp. 553–778; (g) Y. Zhou, J. Wang, Z. Gu, S. Wang, W. Zhu, J. L. Aceña, V. A. Soloshonok, K. Izawa and H. Liu, *Chem. Rev.*, 2016, **116**, 422; (h) M. D. Dutov, V. V. Kachala, B. I. Ugrak, V. A. Korolev, S. V. Popkov, D. R. Aleksanyan, O. N. Rusina, K. G. Aleksanyan and V. N. Koshelev, *Mendeleev Commun.*, 2018, **28**, 437; (i) A. E. Ivanova, Ya. V. Burgart, V. I. Saloutin, Ya. R. Orshanskaya and V. V. Zarubaev, *Mendeleev Commun.*, 2018, **28**, 52.
- (a) A. Kreutzberger and M. Leger, *Arch. Pharm. (Weinheim, Ger.)*, 1982, **315**, 438; (b) M. V. Goryaeva, Ya. V. Burgart and V. I. Saloutin, *Russ. J. Org. Chem.*, 2010, **46**, 432 (*Zh. Org. Khim.*, 2010, **46**, 437); (c) M. V. Goryaeva, Ya. V. Burgart, V. I. Saloutin and O. N. Chupakhin, *Chem. Heterocycl. Compd.*, 2012, **48**, 372 (*Khim. Geterotsikl. Soedin.*, 2012, 395); (d) A. L. Krasovsky, A. S. Hartulyari, V. G. Nenajdenko and E. S. Balenkova, *Synthesis*, 2002, 133; (e) A. L. Krasovsky, A. M. Moiseev, V. G. Nenajdenko and E. S. Balenkova, *Synthesis*, 2002, 901; (f) N. Zanatta, S. S. Amaral, A. Esteves-Souza, A. Echevarria, P. B. Brondani, D. C. Flores, H. G. Bonacorso, A. F. C. Flores and M. A. P. Martins, *Synthesis*, 2006, 2305.
- M. Kawase, M. Hirabayashi, S. Saito and K. Yamamoto, *Tetrahedron Lett.*, 1999, **40**, 2541.
- J.-P. Bouillon, Z. Janousek, H. G. Viehe, B. Tinant and J.-P. Declercq, *J. Chem. Soc., Perkin Trans. 1*, 1995, 2907.
- D. L. Chizhov, D. V. Belyaev, D. S. Yachevskii, G. L. Rusinov, O. N. Chupakhin and V. N. Charushin, *J. Fluorine Chem.*, 2017, **199**, 39.
- D. L. Chizhov, M. G. Pervova, M. A. Samorukova, E. F. Khmara, V. I. Filyakova, V. I. Saloutin and V. N. Charushin, *J. Fluorine Chem.*, 2011, **132**, 394.
- S. Fustero, R. Román, J. F. Sanz-Cervera, A. Simón-Fuentes, A. C. Cuñat, S. Villanova and M. Murguía, *J. Org. Chem.*, 2008, **73**, 3523.

Received: 8th October 2018; Com. 18/5713